Skip to content
10-Q

Quarterly Report

CATALENT PHARMA SOLUTIONS, INC.

0001416083-14-000011

← back to feed
Filed
Apr 23, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2014 · Apr 21, 2014 100 sh
Operating Cash Flow Q3 2014 · Mar 31, 2014 $93.3M
Operating Cash Flow Q3 2014 · Mar 31, 2013 $83.2M
Long Term Debt Q3 2014 · Mar 31, 2014 $2.67B
Long Term Debt Q3 2014 · Jun 30, 2013 $2.66B
Short Term Debt Q3 2014 · Mar 31, 2014 $27.2M
Short Term Debt Q3 2014 · Jun 30, 2013 $35M
Cash And Equivalents Q3 2014 · Mar 31, 2014 $55.7M
Cash And Equivalents Q3 2014 · Jun 30, 2013 $106.4M
Cash And Equivalents Q3 2014 · Mar 31, 2013 $87.5M
Cash And Equivalents Q3 2014 · Jun 30, 2012 $139M
Stockholders Equity Q3 2014 · Mar 31, 2014 −$400M
Stockholders Equity Q3 2014 · Jun 30, 2013 −$410.7M
Current Liabilities Q3 2014 · Mar 31, 2014 $413.3M
Current Liabilities Q3 2014 · Jun 30, 2013 $410.3M
Current Assets Q3 2014 · Mar 31, 2014 $627.4M
Current Assets Q3 2014 · Jun 30, 2013 $677.9M
Total Assets Q3 2014 · Mar 31, 2014 $3.09B
Total Assets Q3 2014 · Jun 30, 2013 $3.06B
Sga Expense Q3 2014 · Mar 31, 2014 $87.6M
Sga Expense Q3 2014 · Mar 31, 2014 $256.2M
Sga Expense Q3 2014 · Mar 31, 2013 $83.7M
Sga Expense Q3 2014 · Mar 31, 2013 $251.7M
Net Income Q3 2014 · Mar 31, 2014 $6.7M
Net Income Q3 2014 · Mar 31, 2014 −$11M
Net Income Q3 2014 · Mar 31, 2013 −$18.8M
Net Income Q3 2014 · Mar 31, 2013 −$65.9M
Operating Income Q3 2014 · Mar 31, 2014 $60.2M
Operating Income Q3 2014 · Mar 31, 2014 $139.8M
Operating Income Q3 2014 · Mar 31, 2013 $47.9M
Operating Income Q3 2014 · Mar 31, 2013 $125.9M
Gross Profit Q3 2014 · Mar 31, 2014 $151.7M
Gross Profit Q3 2014 · Mar 31, 2014 $408.3M
Gross Profit Q3 2014 · Mar 31, 2013 $137.4M
Gross Profit Q3 2014 · Mar 31, 2013 $394.9M
Cost Of Revenue Q3 2014 · Mar 31, 2014 $301.4M
Cost Of Revenue Q3 2014 · Mar 31, 2014 $899.8M
Cost Of Revenue Q3 2014 · Mar 31, 2013 $309.6M
Cost Of Revenue Q3 2014 · Mar 31, 2013 $900.2M